Literature DB >> 19241254

Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery.

Osvaldo Martinez1, Tshidi Tsibane, Christopher F Basler.   

Abstract

The human antibody response to influenza virus infection plays a protective role against re-infection, yet little molecular detail is available regarding how human antibodies, when characterized at the monoclonal level, neutralize this important human pathogen. Recent studies, using a diverse array of strategies, have isolated and characterized human anti-virus neutralizing antibodies and shed light not only on the specificity and origin of these antibodies but on their potential for therapeutic use against influenza virus infection.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19241254     DOI： 10.1080/08830180802593540

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN： 0883-0185            Impact factor:   5.311


  17 in total

1.  Evaluation of diagnostic applications of monoclonal antibodies against avian influenza H7 viruses.

Authors:  Ming Yang; Alfonso Clavijo; Jill Graham; John Pasick; James Neufeld; Yohannes Berhane
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

Review 2.  Evasion of innate and adaptive immune responses by influenza A virus.

Authors:  Mirco Schmolke; Adolfo García-Sastre
Journal:  Cell Microbiol       Date:  2010-05-06       Impact factor: 3.715

3.  Epidemiological and genetic characterization of pH1N1 and H3N2 influenza viruses circulated in MENA region during 2009-2017.

Authors:  Hebah A Al Khatib; Asmaa A Al Thani; Imed Gallouzi; Hadi M Yassine
Journal:  BMC Infect Dis       Date:  2019-04-11       Impact factor: 3.090

4.  Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

Authors:  David J DiLillo; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

Review 5.  Preventing and treating secondary bacterial infections with antiviral agents.

Authors:  Jonathan A McCullers
Journal:  Antivir Ther       Date:  2011

6.  Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice.

Authors:  Kathryn A Hooper; James E Crowe; Jesse D Bloom
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

Review 7.  HIV-1 and influenza antibodies: seeing antigens in new ways.

Authors:  Peter D Kwong; Ian A Wilson
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

8.  Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel.

Authors:  Matthew C Johns; Angelia A Eick; David L Blazes; Seung-eun Lee; Christopher L Perdue; Robert Lipnick; Kelly G Vest; Kevin L Russell; Robert F DeFraites; Jose L Sanchez
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

9.  Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Erin Petersen; Thomas M Moran; Peter Palese
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.